Ruben Mesa, President and Executive Director of Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, shared a post on LinkedIn:
“Excited to be a co-investigator of the MANIFEST2 trial presented by Alessandro Vannucchi at EHA25. The 72-week data of the combination of Pelabresib plus Ruxolitinib showed durably superior responses for the combination for control of splenomegaly and dual responders.”
More posts featuring Ruben Mesa.
